SCHEMBL6896536

SCHEMBL6896536

CCc1cc(O)c2c3c(C(=O)OC)cccc3n(Cc3cccc4ccccc34)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 3/20 0.47
MAPK9 P45984 3/20 0.47
MAPK10 P53779 3/20 0.47
MAPT P10636 3/20 0.43
MCL1 Q07820 4/20 0.40
BAD Q92934 4/20 0.40
KDM4E B2RXH2 3/20 0.40
KMT2A Q03164 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 2/20 0.40
USP2 O75604 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PLA2G1B P04054 1/20 0.40
PLA2G2A P14555 1/20 0.40
SLC22A12 Q96S37 1/20 0.40
CMA1 P23946 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.39
CNR2 P34972 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6894406 0.91 MAPK8 (0.42) MAPK8MAPK9MAPK10MAPTMCL1
SCHEMBL6776083 0.90 PLA2G1B (0.42) MCL1BADKDM4EKMT2AMEN1
SCHEMBL6896629 0.89 MAPK8 (0.47) MAPK8MAPK9MAPK10MAPTMCL1
SCHEMBL6690168 0.88 MAPK8 (0.53) MAPK8MAPK9MAPK10MAPTMCL1
SCHEMBL6895068 0.88 MAPK8 (0.47) MAPK8MAPK9MAPK10MAPTMCL1
SCHEMBL6894723 0.88 MAPT (0.45) MAPTKDM4EKMT2AALDH1A1HPGD
SCHEMBL6892764 0.87 LMNA (0.44) MAPTKDM4EKMT2AALDH1A1MEN1
SCHEMBL6890571 0.87 MAPT (0.45) MAPTKDM4EKMT2AALDH1A1HPGD
SCHEMBL6892130 0.87 HSP90AA1 (0.38) MAPTKDM4EKMT2AALDH1A1HPGD
SCHEMBL6894814 0.86 MAPT (0.44) MAPTKDM4EKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed